This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Epidemiology

Authoring team

The annual incidence of CML is 4.2 cases per 100,000 and it can occur at any age although it is rare in children (CML represents only 5% of childhood leukaemia). The median age at diagnosis is 72 years (1)

CML represents about 15% of all adult leukaemias. (2)

  • CML is more common in males (age-adjusted rate of new cases per 100,000 people [all races] 2.5 males:1.5 females) (3)
  • chronic granulocytic leukaemia is the most common variant of CML
  • in the UK, peak incidence is greatest in the 85 to 89 years age group.(4)

Reference:

  1. Chronic myeloid leukaemia: European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020)
  2. Granatowicz A et al. An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean J Fam Med. 2015 Sep;36(5):197-202.
  3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia - chronic myeloid leukemia (CML). 2024 [internet publication].
  4. Cancer Research UK. Chronic myeloid leukaemia (CML) incidence statistics [internet publication].

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.